Echinocandins for candidemia [14]

New England Journal of Medicine

Volumn 355, Issue 26, 2006, Pages 2791-2792

  Garcia Vidal, Carolina ^a   Carratalà, Jordi ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ECHINOCANDIN; FLUCONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

BLOOD CULTURE; CANDIDEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG POTENCY; DRUG SENSITIVITY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; FUNGUS ISOLATION; HUMAN; LETTER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; YEAST; CANDIDIASIS; FUNGEMIA; NOTE;

ANTIFUNGAL AGENTS; CANDIDIASIS; FLUCONAZOLE; FUNGEMIA; HUMANS; PYRIMIDINES; TRIAZOLES;

EID: 33845899993     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc062805     Document Type: Letter

References (4)

1. Bennett JE. Echinocandins for candidemia in adults without neutropenia. N Engl J Med 2006;355:1154-9.
2. Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005;366:1435-42.
3. Ostrosky-Zeichner L, Rex JH, Pappas PG, et al. Antifungal susceptibility survey of 2000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003;47:3149-54.
4. Panackal AA, Gribskov JL, Staab JF, et al. Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. J Clin Microbiol 2006;44:1740-3.